Aerska Strengthens Board with Appointments of Uli Stilz and Itziar Canamasas

Aerska, a biotechnology company using brain shuttle technology to develop RNA medicines for CNS diseases, today announces the appointment of Itziar Canamasas and Uli Stilz to the Company’s Board of ...
MobiHealthNews

Aerska raises $39M for brain shuttle technology

Aerska, which uses brain shuttle technology to deliver RNAi therapeutics to the brain, announced the close of a $39 million Series A financing round, bringing its total funding to $60 million. EQT ...

Getting Alzheimer’s drugs into the brain is hard. Now there’s a new trick.

The drug industry has been working on how to shuttle drugs through the blood-brain barrier, and the results will become ...

As amyloid falls out of favor, here’s where Alzheimer’s R&D is headed next

Amyloid is increasingly ceding ground in Alzheimer’s disease R&D to new approaches targeting inflammation, immune processes, ...
ALZFORUM

Trontinemab Fuels Hope for Brain Shuttle Lift-Off

Talk about a closely watched study. Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing morsels of news from sequential interim ...